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Regional variation in surgery for  
pancreatic cancer in Denmark 2011-2015
Kasper Wennervaldt1, Anne Mette Kejs1, Henriette Lipczak1, Paul Bartels2, Michael Borre3, 4, Claus Wilki Fristrup5 & Henrik Kehlet6 
To provide the best possible cancer care in Denmark, 
the government and the Danish Regions introduced na-
tionally integrated cancer patient pathways in 2007. 
The aim was to shorten waiting times and increase sur-
vival rates by implementing organisational and clinical 
standards for the diagnostics and treatment of cancer. 
This implementation has led to a significant reduction 
in waiting time, which potentially could contribute to 
an increase in the overall survival [1], but the direct 
causality has yet to be determined. Surgery is an essen-
tial part of cancer treatment. However, little knowl-
edge about the regional variation related to this inter-
vention is available. 
A collaborative of representatives from the Danish 
Cancer Society, the Danish Multidisciplinary Cancer 
Groups, the Danish Regions and the Danish Clinical 
Registries formed a partnership to analyse regional var-
iation in quality and patient safety in Denmark and ide-
ally to propose improvement initiatives within surgical 
cancer treatment in selected areas. The present study 
on pancreatic cancer surgery is part of that work.
Surgery is the cornerstone in the treatment of pan-
creatic cancer with a curative intent, but even in combi-
nation with medical oncology the disease carries a high 
risk of morbidity and mortality. The past two decades 
have seen a rise in both incidence and mortality of pan-
creatic cancer in Denmark [2]. In the same period, pan-
creatic surgery has been extensively centralised from 
12 performing units in 2001 to five in 2008 and four at 
the moment. The reorganisation was, in part, based on 
findings from two earlier studies that documented a 
considerable variation in hospitalisation, readmissions 
and mortality [3, 4]. The reduction of the number of 
performing units to the present level has not been for-
mally evaluated, and the effect on patient outcomes re-
mains unknown.
This study aims to describe regional variation 
within pancreatic surgery in Denmark focusing on 
length of stay, readmission rates and mortality.
METHODS
We performed a retrospective cohort study of all pa-
tients in Denmark with pancreatic cancer (Interna-
tional Classification of Diseases, 10th revision (ICD10): 
C25.1-3 and C25.5-9) who underwent one of four types 
of elective cancer resections: pancreaticoduodenec-
tomy (PD), distal, total and local pancreaticoduodenal 
resection
(KJLC 00/10/20/30/40/50/60/96). Neuro endo-
crine malignancies (C25.4) as well as malignancies of 
the small intestines (C17) and the bile duct (C24) were 
excluded. Procedures classified as experimental, part of 
a protocol or performed outside the four hospitals ap-
proved for cancer surgery by the Danish Health 
Authority were likewise excluded.
We obtained data from the Danish National Patient 
Registry (DNPR) and the National Pathology Data Bank 
(Patobank) for the period from 1 January 2011 to 30 
June 2015. The DNPR was used to create entry records 
that were then cross-referenced to Patobank to obtain 
supplemental data on Tumour-Node-Metastasis (TNM) 
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INTRODUCTION: Surgical treatment for pancreatic cancer 
carries a high risk of both morbidity and mortality. Even so, it 
remains the best curative treatment option. In Denmark, 
pancreatic surgery has been extensively centralised since 
the millennium, but the effect of this centralisation on 
patient outcome has not been evaluated. This study 
describes regional variation within pancreatic surgery on a 
malignant indication, focusing on production volume, length 
of stay, readmission rates and mortality.
METHODS: This is a retrospective cohort study of all 
patients with pancreatic cancer who underwent surgical 
treatment in Denmark from 2011 to 2015. We obtained data 
from the Danish National Patient Registry and the National 
Pathology Data Bank on length of stay, transfers, mortality 
(both short and long term), age, co-morbidity, and disease 
stage.
RESULTS: Four hospital units performed a total of 691 
surgical procedures (476 pancreaticoduodenectomies) in 
the study period. Production volume varied considerably 
across units with two units accounting for nearly 80% of 
surgery performed. Data revealed variation on rates of 
transfers and readmissions as well as disease stage and 
mortality (both short and long term).
CONCLUSIONS: DATA suggest that mortality is linked to 
production volume as well as disease stage, but the small 
data quantity impedes rigorous statistical analysis. Further 
studies on the observed associations are required.
FUNDING: none.
TRIAL REGISTRATION: not relevant..
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TABLE 1
Regional and national data on patients undergoing pancreaticoduodenectomy for malignan-
cies.
Regional, unit no.
National1 2 3 4
Volume 2011-2015, cases 253 121 46 56 476
Average annual production, patients 56 27 10 12 106a
Length of stay, days (median)
Surgical 14.1 (12) 13.9 (10) 17.2 (14) 16.6 (14) 14.6 (2)
Total 17.1 (14) 17.7 (12) 18.2 (14) 17.3 (14) 17.4 (14)
Complex admissionb 
Rate, % 16.6 43.0 13.0 5.4 21.6
Subsequent length of stay, days 18.3 9.0 7.5 13.0 12.8
Readmissions
Total rate, % 27.6 23.3 31.8 23.1 26.4
Mortality rate, %
Hospital   1.2   4.1   4.3   7.1   2.9
30-day   2.0   3.3   4.3   3.6   2.7
90-day   3.6   5.8   6.5   7.2   4.8
180-day 10.3 10.8   8.7 12.6 10.5
1-yr 24.9 29.8 37.0 25.1 27.3
TNM rate, %
Preoperative:
Indicated, any stage 20.9 54.5 8.7 19.6 28.2
Post-operative:
No stage   2.4   3.3 13.0   0.0   3.6
Stage I   9.5 19.0 21.8   5.4 12.5
Stage II 75.5 70.2 63.0 89.3 74.5
Stage III   6.7   5.8   2.2   3.6   5.6
Stage IV   5.9   1.7   0.0   1.7   3.8
Disease stage, rate, %
Burden of disease 12.6 7.4 2.2 5.4 9.5
Gender, males, % 51 51 54 57 52
Age & co-morbidity
CACI (median) 3.0 (3) 2.9 (3) 2.7 (3) 2.6 (3) 2.9 (3)
CCI +3c, rate, % 9.1 7.4 4.3 7.1 8.0
CACI = Charlson Age Comorbidity Index; CCI = Charlson Comorbidity Index; TNM = tumour-node-metastasis.
a) Accumulation does not match due to rounding up. 
b) The patient is transferred to another unit/hospital. 
c) 70-79-yr-olds.
using SNOMED codes for pancreas, ductus-, caput-, 
corpus-, cauda pancreaticus, and papilla et ampulla va-
teri (SNOMED T5900, T59010, T59100, T59200, 
T59300, and T58700). The wider search in Patobank 
was chosen not to overlook any cases while allowing 
the ICD-10 codes to define the population.
We collected data on date of admission and surgery, 
transfers and discharges, hospital and unit identity, 
type of hospitalisation, surgical procedure, primary and 
secondary diagnosis, age, co-morbidity, and TNM.
Descriptive statistics
Three main indicators were defined and calculated: 
length of stay, readmissions, and mortality. These indi-
cators were used for each procedure, at both a national 
and a regional (performing units) level.
Length-of-stay comprises: 
 ▶ Surgical: number of days from the first admission 
day at the surgical unit until discharge.
 ▶ Total: number of days from the first admission day 
at the surgical unit until complete discharge includ-
ing any transfer to units within the hospital or other 
hospitals.
 ▶ Complex admissions: number of admissions in 
which the patient is transferred to another unit or 
hospital.
 ▶ The subsequent length of stay: number of days spent 
at receiving unit or hospital after transfer (complex 
admissions).
Readmissions include:  
 ▶ Readmissions: number of any unplanned readmis-
sion to any hospital in Denmark within 30 days from 
discharge from any hospital, following one of the 
defined procedures. The indicator included all diag-
noses except for trauma.
Mortality covers: 
 ▶ Hospital mortality: number of deaths within pri-
mary hospitalisation until one year after the date of 
the procedure, including death after transfer (com-
plex admissions).
 ▶ 30-day mortality: number of deaths until 30 days af-
ter the date of the procedure.
 ▶ 90-day mortality: number of deaths until 90 days af-
ter the date of the procedure.
 ▶ 180-day mortality: number of deaths until 180 days 
after the date of the procedure.
 ▶ One-year mortality: number of deaths until 365 
days after the date of the procedure.
By dividing the number of deaths by the total number 
of procedures, rates were calculated for all the mortal-
ity indicators.
Burden of disease, age, and co-morbidity served to 
adjust for case mix on a national level and for each of 
the performing units, as follows:
 ▶ Disease stage (DS): the most comprehensive TNM 
(both pre- and postoperative) extracted from TNM 
data limited to 90 days before and after the date of 
surgery.
 ▶ Burden of disease (BOD): percentage of patients 
with disease stage III and IV. 
 ▶ Charlson Age Comorbidity Index (CACI): the origi-
nal Charlson Comorbidity Index (CCI) plus one 
point per age decade from 50 years and upwards. 
The scores were cumulated from 10 years to 90 days 
before the date of surgery. 
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All indicators were calculated for all of the included 
pancreatic procedures in total and for PD separately.
Trial registration: not relevant.
RESULTS 
A total of 691 patients underwent surgery during the 
study period (from 1 January 2011 to 30 June 2015) 
with a male to female ratio of 52:48. Of these, 476 
(68.9%) were treated with PD, 126 (18.2%) with total 
pancreaticoduodenal resection, 85 (12.3%) with distal 
pancreaticoduodenal resection and 4 (0.6%) with local 
pancreaticoduodenal resection; the latter only in one 
unit. No patient received more than one of the four pro-
cedures.
Further analysis is focused on PD exclusively.
Volume varied within the four units (Table 1). The 
two most productive units (1 and 2) accounted for 374 
(79%) of the procedures. The average annual produc-
tion in Denmark was 106 patients (range 10 - 56 per 
unit). There was an increase in volume for all units dur-
ing the observation period.
Mean length of stay after PD was 14.6 days (median 
12 days) at the performing surgical unit, but 17.4 days 
(median 14 days) when including all transfers. The sur-
gical mean varied between the hospitals by 3.4 days 
(range 13.9 – 17.2 days). Of 476 hospitalisations, 103 
(21.6%) were complex with considerable variation be-
tween the units (range: 5.4 - 43.0%). On average, pa-
tients spent 12.8 days at the receiving unit after trans-
fer.
Readmissions within 30 days from discharge oc-
curred a total of 122 times (26.4%) and with some var-
iation between the units (range: 23.1 - 31.8%).
Hospital mortality included no deaths during sur-
gery, but 14 patients (2.9%, range: 1.2 - 7.1%) died be-
fore discharge. 30-day mortality showed that 13 pa-
tients (2.7%, range: 2.0 - 4.3%) died within a month, 
90-day mortality included 23 patients (4.8%, range: 
3.6 - 7.2%), 180-day mortality 50 patients (10.5%, 
range: 8.7 - 12.6%) and one-year mortality 130 pa-
tients (27.3%, range: 24.9 - 37.0%).
See Figure 1 for one-year survival follow-up.
Data on DS were available for all patients (476). 
The preoperative stage was stated for 134 patients 
(28.2%, range: 8.7 - 54.5%). Postoperative staging was 
stated for 459 patients (96.4%) with less variation be-
tween the units (range: 87.0 - 100.0%). A majority of 
355 patients (74.5%) were in disease stage II. The BOD 
varied more than fivefold between the units with the 
highest and lowest score (range 2.2 - 12.6%). Data on 
age and co-morbidity were obtained for all patients, 
and the mean CACI was 2.9, with almost no variation 
across the units. 
All indicators were also calculated for pancreatic 
surgery overall (all included procedures) with results 
very similar to those for PD.
DISCUSSION
This study includes all pancreatic surgery on pancreatic 
cancers in Denmark from 2011 thr0ough to the first 
half of 2015 as registered in the DNPR. Compared with 
previous Danish studies on PD, the national annual 
production volume on malignant indication has in-
creased from 56 patients in 1996-2001 [3], to 74 pa-
tients in 2005-2008 [4] and 106 patients in our study 
period. The increase in national production is possibly 
a consequence of the rise in incidence as well as pro-
gression in surgical skills and knowledge. Although the 
centralisation of cancer surgery over the past two de-
cades has reduced the number of performing units, it 
has not led to an even distribution in production vol-
ume. Currently, almost 80% of the procedures is per-
formed in two of the four units, with one unit account-
ing for more than 50% of all operations in Denmark.
The median length of stay has declined from 22 
days in 1996-2001 [3], to 17 days in 2005-2008 [4] 
and 12 days in this study period. The rate of complex 
FIGURE 1
Kaplan-Meier follow-up until one-year survival for each of the four units.
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admissions varied considerably between the units 
(range: 5.4 - 43.0%), but it is unknown whether trans-
fers were planned or acute. Regardless hereof, these 
situations present a potential threat to patient safety 
because hand-overs - whether temporary or perma-
nent, are a complicated process which often requires a 
high level of awareness and preparedness within com-
munication, information, responsibility and organisa-
tion [5].To our knowledge, complex admission rates 
have not been reported in previous Danish or interna-
tional studies of this kind. Readmission rates were re-
markably higher in this study than previous national 
findings ranging from 10% in 1996-2001 [3], 11% in 
2005-2008 [4] to 26.4% in the present study. It re-
mains unknown whether this is linked to the observed 
decline in length of stay or complex admissions. 
Compared with international findings, length of stay 
[6-12] and readmission rates [10, 13] are roughly on a 
par, although data on readmission rates are sparse.
In Denmark, hospital mortality following PD on 
cancer has declined considerably from 11.3% in 1996-
2001 [3] to 6.0% in 2005-2008 [4], and the presently 
recorded 2.9%. This national average is at the low end 
of internationally reported rates [6, 7, 12-16], thereby 
matching the performance of high-volume centres. 
Hospital mortality varied the most within the studied 
mortality indicators. The specifics about this are un-
known, but international observations suggest that 
some of these types of deaths are potentially prevent-
able [17]. Causality cannot be inferred from this study, 
but is most likely multifactorial. The phenomenon “fail-
ure-to-rescue” - the challenge to intervene sufficiently 
towards postoperative complications - could be a con-
tributor to this [17], but this cannot be evaluated in the 
present study. 30-day mortality declined from 5.9% in 
1996-2001 [3] to 2.7% at present. The remaining mor-
tality indicators revealed little variation between the 
units except for one-year mortality, which also showed 
some variation. Previous national data on this indicator 
do not exist, but compared with international observa-
tions, the current national average is at the low end [6, 
12]. Direct comparison with earlier national findings 
should be interpreted with some caution as these stud-
ies include approximately 10% of patients with benign 
conditions as well. 
The burden of disease varied between the units. 
This variation has also been documented by the Danish 
Pancreatic Cancer Database (DPCD). Arterial resec-
tions are performed only in one unit, thus treating the 
more advanced cancers. However, this cannot fully ex-
plain the observed difference. The TNM classification 
has changed during the study period, and this could in-
fluence the reported tumour stages. A potential prob-
lem has been a non-standardised evaluation of the re-
sected specimen, which could affect the accuracy of the 
TNM staging and margin evaluation between units. As 
a consequence, the DPCG has implemented a national 
standardised pathology protocol, which will hopefully 
align the TNM classification nationwide.
Overall, the population-based resection rate in 
Denmark is on a par with international levels [18], but 
the absolute number of annual PDs in Denmark is low. 
The uneven distribution of the production volume di-
vides the four existing units into two high- and two 
low-volume units. The link between volume and mor-
tality – both in the short and long term – has not been 
firmly established in this study (see Figure 2), but mul-
ticentre studies on pancreatic surgery have found a 
positive association between a high resection volume 
and a low mortality [7, 14, 16-19]. Internationally, 
long-term mortality has been associated with a high tu-
mour grade [20], in this study the reverse association 
was suggested for one unit where a low tumour grade 
was associated with the highest one-year mortality.
CONCLUSIONS
This study suggests that a need exists for identification 
of factors potentially contributing to the observed vari-
ations in complex admissions, readmissions and, espe-
cially, mortality. Thus, further studies on the link be-
tween mortality, volume and BOD are required.
The aim of this study was to uncover any regional 
variations in surgical outcomes across the four produc-
ing units. The inequity in the number of patients in 
some units (i.e., those with a very small numbers of pa-
tients) impedes rigorous statistical analysis.
The identified variations illustrate a potential dis-
FIGURE 2
Volume, length of stay, readmissions, and one-year-mortality for PD at each of the performing 
units. Volume is specified on the primary y-axis and mean length-of-stay (surgical), readmis-
sions, and one-year-mortality is specified on the secondary y-axis.
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parity across the country, which might indicate that a 
safety gap exists and future follow-up data are required 
to determine causality.
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